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Abstract
Insulin, as one of the most important hormones regulating energy metabolism, plays
an essential role in maintaining glucose and lipid homeostasis in vivo. Failure or insuffi-
ciency of insulin secretion from pancreatic beta-cells increases glucose and free fatty
acid level in circulation and subsequently contributes to the emergence of hypergly-
caemia and dyslipidaemia. Therefore, stimulating the insulin release benefits the treat-
ment of type 2 diabetes and obesity significantly. Frog skin peptides have been
extensively studied for their biological functions, among which, Phylloseptin peptides
discovered in Phyllomedusinae frogs have been found to exert antimicrobial, antipro-
liferative and insulinotropic activities, while the mechanism associated with Phyl-
loseptin-induced insulin secretion remains elusive. In this study, we reported a novel
peptide named Phylloseptin-PBu, isolated and identified from Phyllomedusa burmeis-
teri, exhibited dose-dependent insulinotropic property in rat pancreatic beta BRIN-
BD11 cells without altering cell membrane integrity. Further mechanism investigations
revealed that Phylloseptin-PBu-induced insulin output is predominantly modulated by
KATP-[K
+] channel depolarization triggered extracellular calcium influx and GLP-1
receptor initiated PKA signalling activation. Overall, our study highlighted that this
novel Phylloseptin-PBu peptide has clear potential to be developed as a potent antidi-
abetic agent with established function-traced mechanism and low risk of cytotoxicity.
K E YWORD S
calcium, GLP-1 receptor, insulin release, peptide, PKA signalling, potassium channel
1 | INTRODUCTION
Type 2 diabetes mellitus (T2DM), accounting for almost 90% cases
of the disease, has become a global public health threat for both
individuals and social healthcare systems.1 Although the aetiology
of T2DM has not been fully understood, it is widely accepted that
deficiency of insulin secretion from pancreatic beta-cells accompa-
nied by attenuation/abnormality of insulin sensitivity in specific
tissues (liver, heart, fat, skeleton muscle) is the common feature of
T2DM.2 Either beta-cell disorder or decreased beta-cell mass
contributes to the impairment of insulin release.3 Hyperglycaemia
and dyslipidaemia, as hallmarks of T2DM, appear when the blood
glucose and lipid lowering effect of secreted insulin is not
sufficient to compensate for insulin resistance. When patients
suffer the long-term pathological conditions, complications of
T2DM, such as heart and blood vessel diseases, neuropathy,
nephropathy, eye/foot/hearing/skin damage and Alzheimer’s dis-
ease, will occur.4-6
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Clinically, the therapies for the treatment of T2DM are aimed
at decreasing hepatic glucose production, improving insulin resis-
tance and increasing insulin release. In particular, for the insulin
secretion boosting therapy, two types of drugs are currently
prescribed, one acts on closing the KATP channels on the beta-
cells for the calcium influx, and the other type targets on mimick-
ing or enhancing the effect of gut hormones (also named as
incretins),7 a good example of the latter type is extendin-4, it was
firstly isolated and characterized from the Heloderma suspectum
venom, the glycaemic-control action of extendin-4 is via the simi-
lar way with glucagon-like peptide 1 (GLP-1), which mainly attri-
butes to the potentiation of insulin secretion in a glucose-sensing
manner.7-14
Bioactive peptides from amphibian secretions and venoms with
characteristics of diversity and specificity provide candidates for
the development of novel drugs for combatting multiple diseases,
including antibiotic-resistant pathogens caused infections, cancers
and T2DM.15 Previous elegant research has reported that some
frog skin-derived peptides possess the ability to stimulate insulin
release both in vitro and in vivo at relatively low concentration
and dose without causing cellular toxicity.16-18 Many have been
extensively studied in the fields of amino acid isoform replace-
ment, post-translational modification and primary structure modifi-
cation, all of these focus on increasing the insulin release
efficiency, preventing the degradations caused by endogenous
enzymes and improving the cytotoxicity.16,19,20 Nevertheless, the
mechanism associated with how these bioactive peptides are
involved in the insulin release action has rarely been investigated.
Thus, in this study, for the first time, we reported a novel insuli-
notropic peptide isolated from Phyllomedusa burmeisteri, in which
species such peptide has never been identified, belongs to Phyl-
loseptin family, named as Phylloseptin-PBu. At low concentration,
it showed glucose-comparably insulin secretion stimulatory effects
in pancreatic beta BRIN-BD11 cells. Cell signalling examinations
revealed the involvements of KATP-[K
+] channel-induced intracellu-
lar calcium elevation and partial GLP-1 receptor activation-induced
PKA stimulation, which is firstly reported. Therefore, we not only
provide a novel candidate for developing antidiabetic agent,
but also elucidate the preliminary mechanism of its bioactivity,
illuminating the future work for promoting this agent into clinical
tests.
2 | MATERIALS AND METHODS
2.1 | Acquisition of frog skin secretions
The specimens of Burmeister’s leaf frog, Phyllomedusa burmeisteri
(n = 3, 6 and 8 cm snout-to-vent lengths), were sampled in the
Atlantic Forest biome of Brazil. The skin secretions were obtained
by mild transdermal electrical stimulation (5 V, 50 Hz, 4 ms pulse
width).21 The skin secretions were then collected by rinsing with dis-
tilled deionized water and subjected to snap frozen with liquid nitro-
gen, lyophilized and stored at 20°C prior to use.
2.2 | “Shotgun” cloning of a novel Phylloseptin-like
peptide from skin secretion-derived cDNA library
Five milligrams of lyophilized Phyllomedusa burmeisteri secretion
powder was dissolved in 1 mL cell lysis/binding buffer to isolate
polyadenylated mRNA by magnetic oligo-dT beads via using Dyn-
abeads mRNA DIRECTTM Kit (Dynal Biotech, Liverpool, UK). The
reverse-transcription products were subjected to 30-RACE PCR pro-
cedures to acquire the full length of preproprotein nucleic acid
sequences using a SMART-RACE kit (Clontech, Palo alto, CA, USA).
Briefly, a nested universal primer (NUP) (supplied with the kit) and a
degenerate primer (S1; 50-ACTTTCYGAWTTRYAAGMCCAAABAT
G-30, Y = C + T, W = A + T, R = A + G, M = A + C, B = T + C + G)
which was designed on the basis of the 50-untranslated region of
phylloxin cDNA from Phyllomedusa bicolor.22 The PCR cycling was
carried out as follows: initial denaturation step: 90 seconds at 94°C;
35 cycles: denaturation 30 seconds at 94°C, primer annealing for
30 seconds at 58°C; extension for 180 seconds at 72°C. PCR prod-
ucts were gel-purified and cloned using a pGEM-T Easy vector sys-
tem (Promega Corporation, Southampton, UK), and then, selected
samples were sequenced using an ABI 3100 automated sequencer
(Applied Biosystems, Foster City, CA, USA).
2.3 | Identification and structural characterization
of the novel Phylloseptin-like peptide from
Phyllomedusa burmeisteri skin secretion
An aliquot sample of lyophilized skin secretion was dissolved in
1 mL trifluoroacetic acid (TFA)/water (0.05/99.95, v/v) and then
clarified by centrifuge. One millilitre supernatant was decanted and
pumped into reversed phase-HPLC column (Phenomenex C-5,
300 A, 5 lm, 4.5 9 250 mm, Phenomenex, Macclesfield, Cheshire,
UK) using a gradient program. The gradient elution formed from
TFA/water (0.05/99.95, v/v) to TFA/water/Acetonitrile (0.05/19.95/
80.00, v/v/v) in 240 minutes at a flow rate of 1 mL/min, and the
effluent was detected by UV absorbance at 214 and 280 nm. Frac-
tions were collected at 1-minutes interval by an automatic fraction
collector (GE Healthcare, Little Chalfont, UK). The molecular mass of
each fraction was analysed using the matrix-assisted laser desorption
ionization time of flying (MALDI-TOF) mass spectrometer (Voyager
DE, PerSeptive Biosystems, Foster City, CA, USA) with a-cyano-4-
hydroxycinnamic acid (CHCA) matrix in positive detection mode.
Fractions with the molecular weight coincidence with the mature
peptide which is predicted from cloned cDNA were then subjected
to primary structural analysis by MS/MS fragmentation using a liquid
chromatography quadrupole (LCQ)-Fleet electrospray ion-trap mass
spectrometer (Thermo Fisher Scientific, San Francisco, CA, USA).
2.4 | Solid phase peptide synthesis of Phylloseptin-
PBu
Once the primary structural of the Phylloseptin-PBu was unequivo-
cally confirmed through both MS/MS fragmentation sequencing and
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molecular cloning, the solid-phase Fmoc strategy was adopted via
TributeTM automated solid-phase peptide synthesizer 4 (Protein
Technologies, Tucson, AZ, USA) to synthesize the novel peptide as
previously described.23 The synthesized peptide replicates were puri-
fied by reverse phase HPLC with C18 column (Jupiter C18, 5 lm
particle, 300 A pore, 250 9 10 mm, Phenomenex, UK), and both
molecular masses and high-purity of the synthetic replicates were
confirmed via MALDI-TOF.
2.5 | Determination of peptide secondary
structures using circular dichroism (CD) analysis
CD measurements were performed using a JASCO J-815 CD spec-
trometer (Jasco, Essex, UK) at room temperature (20-25°C). Peptide
was dissolved in (i) water, (ii) 50% (v/v) trifluoroethanol (TFE)-water
and (iii) 50% (v/v) Methanol-water to reach a final concentration of
100 lmol/L before transferred and measured in a 0.1-cm-high preci-
sion quartz cell (Hellma Analytics, Essex, UK). The wavelength was
from 190 to 260 nm with a scanning speed of 200 nm/min, the
bandwidth and data pitch are 1 and 0.5 nm, respectively. CD data
are expressed as the mean residue ellipticity [h] in deg.cm2.dmol1 in
corresponding wavelength (nm), which is calculated from the mea-
sured ellipticity (h, in medg) using the equation [h] = h/(10 9 c 9 l),
where “c” is the molar concentration of the sample (M) and “l” is the
cuvette path length in centimetre. DICHROWEB webserver (http://
dichroweb.cryst.bbk.ac.uk/html/home.shtml) was used to estimate
the a-helix and b-sheet content.24-26
2.6 | Cell line and cell culture
The BRIN-BD11 rat clonal beta-cell line is purchased from European
Collection of Authenticated Cell Cultures (Catalogue No. 10033003,
UK), which serves as a canonical in vitro model to study insulin
release in response to nutrients and chemicals.27 After resuscitation,
BRIN-BD11 cells were cultured using RPMI-1640 medium (Invitro-
gen, Paisley, UK) containing 10% (v/v) foetal bovine serum (FBS)
(gibco, UK), antibiotics (100 U/mL penicillin, 0.1 mg/mL strepto-
mycin, gibco, UK) and 11.1 mmol/L D-glucose at 37°C with 5%
CO2.
2.7 | Measurement of acute insulin secretion using
rat insulin ELISA
BRIN-BD11 cells were seeded into 24-well plates (Nunc, Roskilde,
Denmark) with the density of 3 9 105 cells/well for 24-hours incu-
bation. After then, cells were pre-incubated for 40 minutes at 37°C
in Krebs Ringer Bicarbonate (KRB) buffer (115 mmol/L NaCl,
4.7 mmol/L KCl, 1.28 mmol/L CaCl2, 1.2 mmol/L KH2PO4,
1.2 mmol/L MgSO4,10 mmol/L NaHCO3, pH 7.4) supplemented with
1.1 mmol/L glucose and 0.1% (w/v) bovine serum albumin (BSA)
(Sigma, UK). Acute administration of a concentration gradient (1012
to 107 mol/L) of purified synthetic Phylloseptin-PBu was performed
(n = 5) in the presence of 5.6 mmol/L or 16.7 mmol/L glucose in
KRB buffer for 20 minutes at 37°C. After which, aliquots of cell cul-
ture supernatant from each well were collected and measured using
Ultra-Sensitive Rat Insulin ELISA kit (Crystal Chem Inc, USA) accord-
ing to the manufacturer’s instruction.
For cell signalling studies, 300 lmol/L diazoxide (Sigma, UK),
60 lmol/L verapamil (Sigma, UK), 200 lmol/L IBMX (Tocris Bio-
science, UK), 10 lmol/L H89 (Tocris Bioscience, UK) and 1 lmol/L
Exendin (9-39) amide (Tocris Bioscience, UK) were pre-treated
30 minutes before Phylloseptin-PBu stimulation unless specific
states.
All cell culture designs for the ELISA measurement were
repeated with three independent studies, and every study contains
three replicates for each treatment.
2.8 | Cell membrane integrity, haemolytic and
antimicrobial evaluations
The lactate dehydrogenase (LDH) assay was employed to assess the
cell membrane integrity after Phylloseptin-PBu treatment. The rate
of LDH release from BRIN-BD11 cells was measured using Pierce
LDH Cytotoxicity Assay Kit (Thermo scientific, USA) according to
the manufacturer’s instruction with the cell culture supernatant col-
lected from acute insulin release assay.
Peptide concentrations range from 107 to 1012 mol/L was
prepared for assessing the haemolytic and antimicrobial properties of
Phylloseptin-Pbu, and the detailed procedures were described
previously.28
2.9 | Western blotting
BRIN-BD11 cells were seeded into 100-mm tissue culture dishes at
a density of 2 9 106 cells/dish for 24 hours prior to 6-hours serum-
free starvation, Phylloseptin-PBu (107 mol/L) was then added for
16-hours incubation. The cells were rinsed twice with ice-cold PBS,
solubilized in lysis buffer containing 50 mmol/L Tris (pH 7.5), 1%
Nonidet P-40, 150 mmol/L NaCl, 2 mmol/L EGTA, 1 mmol/L
Na3VO4, 100 mmol/L NaF, 10 mM Na4P2O7, 1 mmol/L phenyl-
methylsulfonyl fluoride, 10 lg/mL aprotinin and 10 lg/mL leupeptin.
After centrifugation at 14 0009 g for 10 minutes at 4°C, the super-
natant was boiled for 5 minutes in SDS-PAGE sample buffer
[50 mmol/L Tris-Cl (pH 6.8), 2% sodium dodecyl sulphate, 10% glyc-
erol, 2% b-mercaptoethanol and 0.004% bromophenol blue] and sep-
arated by 7.5% SDS-PAGE, and transferred to nitrocellulose
membrane (GE Healthcare Life sciences, UK), and detected by Wes-
tern blotting with the indicated antibody (Cell Signaling Technology,
UK) using enhanced chemiluminescence [Pierce ECL Western Blot-
ting Substrate (Thermo scientific, USA)], and imaged via Chemi DocTM
MP system (Bio-Rad, UK).
The antibodies that chosen for the present study were PKA-Ca
(1:1000; Cell Signaling, #4782), phospho-PKA-C (Thr197) (1:1000;
Cell Signaling, #5661), GAPDH (1:1000; Cell Signaling, #5174) and
Anti-rabbit IgG, HRP-linked Antibody (1:2000; Cell Signaling,
#7074).
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2.10 | Statistical analysis
All results are presented as mean  SEM determined by two-tailed
Student’s t test or one-way ANOVA. Pairs comparisons of the means
were made, and P < .05 was regarded as a significant difference.
The Bonferroni method was used to adjust the observed significance
levels for the fact the multiple contrasts were being tested.
3 | RESULTS
3.1 | Primary structure identification and synthesis
of novel peptide Phylloseptin-PBu
From the skin secretion of Phyllomedusa burmeisteri-derived cDNA
library, the cDNA encoding the biosynthetic precursor of Phyl-
loseptin-PBu consistently and repeatedly cloned. The coding region
of the cDNA consisted of 66 amino acids which can be divided into
four domains: the putative signal peptide, which is located at the 50-
termius with 22 amino acids; the 24-residue acidic spacer domain, a
typical Lys-Arg (K-R) propeptide convertase processing site and the
19-mer mature peptide named Phylloseptin-PBu (FLSLLPHIAS-
GIASLVSKF-NH2) (Figure 1A). The peptide Phylloseptin-PBu
sequence showed high similarity with phylloseptin-S6 (EMBL acces-
sion number: HE974361), phylloseptin-S1 (AM903077), phylloseptin-
S3 (AM903079) and phylloseptin-S2 (AM903078) from Phyllomedusa
sauvagii (Figure 1B). The nucleotide sequence of the cDNA encoding
the novel Phylloseptin-PBu precursor from the skin secretion of
Phyllomedusa burmeisteri has been deposited in the EMBL Nucleotide
Sequence Database under the accession code: LT841135.
The rp-HPLC fractions collected from crude skin secretion of
Phyllomedusa burmeisteri (Figure 1C) were all analysed by matrix
assisted laser desorption ionization time of flight (MALDI-TOF) mass
spectrometry to determine the molecular mass. The effluent showed
the same mass with the putative peptide from molecular cloning was
subjected to liquid chromatography quadrupole (LCQ)-Fleet electro-
spray ion-trap mass spectrometer for primary structural determination
(Figure 1D,E). The mature peptide sequence of Phylloseptin-PBu
ended with amidation, a post-translational modification at
C-terminus, was successfully detected by LCQ MS/MS. Taken
together, the primary sequence of was unequivocally determined as
FLSLLPHIASGIASLVSKF-NH2.
Phylloseptin-PBu peptide replicates were then synthesized by
standard solid-phase Fmoc chemistry using TributeTM automated
solid-phase peptide synthesizer 4 (Protein Technologies, Tucson, AZ,
USA). Following cleavage from the synthesis resin, impurities were
removed from the synthetic replicates by rp-HPLC and the molecular
masses of the purified major products were confirmed by MALDI-
TOF mass spectrometry (Figure S1).
3.2 | Secondary structure determination by circular
dichroism analysis
The CD spectra (Figure 2) indicated that Phylloseptin-PBu displayed
diverse secondary structure conformations in different surroundings.
In aqueous solution, a mixed conformation of random coil (42%) and
b-sheet (51%) was presented with a negative band at 200 nm. A
similar conformation was observed in 50% methanol-water solution
with a slightly higher presence of random coil. By contrast, a typical
a-helical conformation was shown in 50% TFE-water solution with
one positive band at 192 nm and two negative bands at 206 nm
and 222 nm, respectively, and the predicted a-helical contents of
Phylloseptin-PBu were 96% in 50%TFE-water solution. The percent-
age of secondary structure helicity of Phylloseptin-PBu in respective
solutions are shown in Table 1.
3.3 | Phylloseptin-PBu induces insulin release from
BRIN-BD11 cells
To investigate whether Phylloseptin-PBu could stimulate insulin
release, we treated rat pancreatic beta BRIN-BD11 cells with a con-
centration range from 107 to 1012 mol/L, along with a 5.6 mmol/L
glucose group, which mimics the glucose level in physiological condi-
tions, a 16.7 mmol/L glucose group, which is a stimulatory glucose
level (suggesting diabetic ketoacidosis), and a positive alanine group.
The results (Figure 3A) showed that, upon Phylloseptin-PBu stimula-
tion, BRIN-BD11 cells exhibited a significant higher, and a dose-
dependent, insulin release capacity compared with 5.6 mmol/L glu-
cose group, this effect was even stronger than 16.7 mmol/L glucose
group when administered the 107 or 108 mol/L concentration of
the peptide. Although the insulinotropic effect of Phylloseptin-PBu is
weaker compared to L-alanine, which mainly induces insulin output
via Ca2+ influx mechanism,29 it still prompted us to explore the signal
pathways that involved in this novel Phylloseptin-PBu peptide exhib-
ited bioactivity.
As Phylloseptin-like peptides have been reported to exert antimi-
crobial activities against Gram-positive and Gram-negative bacterial
F IGURE 1 A, Nucleotide and translated open-reading frame amino acid sequences of full-length prepro-Phylloseptin-PBu peptide encoding
cDNA from Phyllomedusa burmeisteri (EMBL accession number: LT841135). The putative signal peptide is double-underlined, the mature
peptide is single-underlined and the stop codon is indicated by an asterisk. B, Alignment of cDNA deduced mature Phylloseptin-PBu sequence
with phylloseptin peptides from Phyllomedusa sauvagii species. Highly conserved residues are indicated by asterisks (*). C, Region of rp-HPLC
chromatogram of Phyllomedusa burmeisteri skin secretion with arrow indicating the retention times (at 91 min) of the novel peptide
Phylloseptin-PBu. The detection wavelength was 214 nm with a flow rate of 1 mL/min in 240 min. D, Thermoquest LCQTM fragment scan
spectrum derived from ions corresponding to Phylloseptin-PBu. E, Expected single- and double-charged b- and y-ion series predicted from
LCQ MS/MS fragmentation of Phylloseptin-PBu. The fragment ions observed following actual fragmentation are shown in red (b-ions) and blue
(y-ions) typefaces
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and fungi by disrupting the cell membrane.30 We therefore investi-
gated whether Phylloseptin-PBu-triggered insulin release was caused
by the damage to cell membrane. The minimal inhibitory concentra-
tion (MIC) assay implied that Phylloseptin-PBu possessed no antimi-
crobial activity against S. aureus, E. coli and C. albicans when the
concentration was up to 107 mol/L (Figure S2). The lactate
dehydrogenase (LDH) tests suggested that Phylloseptin-PBu treat-
ment did not compromise cell membrane integrity in BRIN-BD11
cells at concentrations up to 107 mol/L (Figure 3B). Further haemo-
lytic measurement using horse blood cell also did not show cytolytic
effect of Phylloseptin-PBu at 107 mol/L (Figure 3C). Therefore,
these results lead us to investigate the specific mechanism that
related to insulin release effect of Phylloseptin-PBu.
3.4 | Potassium and calcium channel-modulated
Ca2+ influx examination
As indicated, elevated intracellular ATP level and increased ATP/ADP
ratio leads to the closure of potassium channel, induction of cell
#1 b(1+) b(2+) Seq. y(1+) y(2+) #2
1 148.07570 74.54149 F 19
2 261.15977 131.08352 L 1852.10557 926.55642 18
3 348.19180 174.59954 S 1739.02150 870.01439 17
4 461.27587 231.14157 L 1651.98947 826.49837 16
5 574.35994 287.68361 L 1538.90540 769.95634 15
6 671.41271 336.20999 P 1425.82133 713.41430 14
7 808.47162 404.73945 H 1328.76856 664.88792 13
8 921.55569 461.28148 I 1191.70965 596.35846 12
9 992.59281 496.80004 A 1078.62558 539.81643 11
10 1079.62484 540.31606 S 1007.58846 504.29787 10
11 1136.64631 568.82679 G 920.55643 460.78185 9
12 1249.73038 625.36883 I 863.53496 432.27112 8
13 1320.76750 660.88739 A 750.45089 375.72908 7
14 1407.79953 704.40340 S 679.41377 340.21052 6
15 1520.88360 760.94544 L 592.38174 296.69451 5
16 1619.95202 810.47965 V 479.29767 240.15247 4
17 1706.98405 853.99566 S 380.22925 190.61826 3
18 1835.07902 918.04315 K 293.19722 147.10225 2
19 F-Amidated 165.10225 83.05476 1
E
F IGURE 1 (Continued).
F IGURE 2 The Circular Dichroism spectra of Phylloseptin-PBu in
H2O, 50% 2,2,2-trifluoroethanol (TFE)-H2O and 50% Methanol-H2O
TABLE 1 Helicity index of Phylloseptin-PBu analysed according
to CD spectra data using DICHROWEB online server
Percentage of helicity (%) a-helix b-sheet
Random
coil
H2O 7 51 42
50% TFE + H2O 96 0 4
50% Methanol + H2O 8 45 47
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membrane depolarization and opening of voltage-gated calcium chan-
nel. These actions promote extracellular Ca2+ influx, which plays a key
role in mediating L-alanine-activated insulin release from BRIN-BD11
cells.31 We employed diazoxide (activator of ATP-sensitive potassium
channels), verapamil (inhibitor of voltage-gated calcium channels) and
Ca2+-free medium to examine whether Phylloseptin-PBu stimulated
insulin release is via Ca2+ mobilization. As shown in Figure 4, pre-
administration of diazoxide and verapamil significantly attenuated
Phylloseptin-PBu-induced insulin production, deprivation of Ca2+ sig-
nificantly attenuated the insulin producing activity in all tested
groups, but significant enhancement of insulin release was still
observed after Phylloseptin-PBu treatment even culturing the cells
with Ca2+-free KRB buffer with or without diazoxide or verapamil.
Together, these results suggested that calcium influx, mediated by
ATP-sensitive potassium channel induced depolarization and calcium
channel opening, played the dominant role in the insulinotropic
activity of Phylloseptin-PBu, nevertheless, this effect was not com-
pletely abrogated, it prompted us to hypothesize that other sig-
nalling might be involved.
3.5 | PKA signalling activation-modulated insulin
secretion examination
Activation of cAMP/PKA was also reported to elicit insulin secretion
in islet.32 Thus, we interrogated the PKA signalling using the PKA
F IGURE 4 Acute effects (20 min stimulation) of 107 mol/L
Phylloseptin-PBu on the insulin release. BRIN-BD11 cells were
incubated with 1.1 mmol/L glucose, 5.6 mmol/L glucose,
16.7 mmol/L glucose, 10 mmol/L alanine, 300 lmol/L diazoxide,
60 lmol/L verapamil and 107 mol/L Phylloseptin-PBu in the
presence or absence of Ca2+ KRB buffer. Data were analysed with
unpaired Student’s t test using GraphPad Prism 5 software. Values
are the mean  SEM for three independent experiments. *P < .05,
** or ##P < .01, ###P < .001 between indicated groups
F IGURE 3 A, Acute effects (20 min stimulation) of a range
concentration (1012 to 107 mol/L) of Phylloseptin-PBu peptide on
insulin secretion from BRIN-BD11 cells. ***P < .001 vs 5.6 mmol/L
glucose alone. B, Lactate dehydrogenase (LDH) release from BRIN-
BD11 cells after acute stimulation (20 min) of 10 mmol/L alanine
and a range concentration (1012 to 107 mol/L) of Phylloseptin-
PBu. C, the haemolytic activity of a range concentration (1012 to
107 mol/L) of Phylloseptin-PBu was tested on horse red blood
cells. The positive control group was treated with 1% Triton X-100
lysis buffer. Ala, Alanine; Glc, Glucose
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activator (IBMX, 3-Isobutyl-1-methylxanthine) and inhibitor (H89) in
the presence or absence of Phylloseptin-PBu. The results (Figure 5A)
showed that although H89 significantly blunted Phylloseptin-PBu-
induced insulin secretion, compared with singular H89 treatment,
Phylloseptin-PBu still has a trend to increase insulin release. While
IBMX alone and co-administered with Phylloseptin-PBu increased
and dramatically further enhanced insulin output, respectively. Based
on these observations, we speculated that PKA signalling is not only
modulated by Phylloseptin-PBu, but also L-alanine for the stimula-
tion of insulin release from BRIN-BD11 cells.
Furthermore, we used Western blotting to examine the effect of
Phylloseptin-PBu vs IBMX on PKA activation in BRIN-BD11 cells. As
shown in Figure 5B, the phosphorylation level of PKA at Thr197
was markedly elevated by IBMX and Phylloseptin-PBu, which con-
firmed the involvement of PKA cascade in Phylloseptin-PBu-induced
insulinotropic activity.
F IGURE 5 A, Acute effects (20 min stimulation) of 107 mol/L Phylloseptin-PBu on the insulin release. BRIN-BD11 cells were incubated
with 1.1 mmol/L glucose, 5.6 mmol/L glucose, 16.7 mmol/L glucose, 10 mmol/L alanine, 10 lmol/L H89, 200 lmol/L IBMX and 107 mol/L
Phylloseptin-PBu in Ca2+-contained KRB buffer. Data were analysed with unpaired Student’s t test using GraphPad Prism 5 software. Values
are the mean  SEM for three independent experiments. **P < .01, ***P < .001 between indicated groups. B, BRIN-BD11 cells were treated
with 100, 200 lmol/L IBMX or 107 mol/L Phylloseptin-PBu for 2 h, total proteins were extracted. Eighty lg protein was immunoblotted to
determine the abundance of total PKA and phosphor-PKA at Thr 197. Signal intensity was quantified by Image Lab software for statistical
comparison, *P < .05, **P < .01 vs vehicle control
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3.6 | Assessment of GLP-1 receptor activation by
Phylloseptin-PBu
Next, we investigated how Phylloseptin-PBu activated PKA signalling.
As GLP-1 and extendin-4 have been demonstrated to enhance insulin
release in a PKA-dependent manner,7,33-35 we hypothesized that
Phylloseptin-PBu act as an agonist to GLP-1 receptor and contributes
to cAMP/PKA signalling activation. Following on from this, we used
GLP-1 receptor antagonist exendin-(9-39) to examine whether it can
impair Phylloseptin-PBu’s action. As the results shown in Figure 6,
the insulin secretion effect was significantly decreased in both exen-
din-(9-39) and exendin-(9-39) with Phylloseptin-PBu co-incubation
groups; nonetheless, the latter group also showed a prominent higher
insulin output. While further consistently activating KATP channels
with diazoxide or blocking the calcium channels with verapamil
showed an additive insulin secretion inhibition effect. In the mean-
time, the calcium deprivation patterns, again, exhibited significant
lower insulin production, of note is that under such conditions, Phyl-
loseptin-PBu still stimulated higher insulin production. As a whole,
these results confirmed that Phylloseptin-PBu could interact with
GLP-1 receptor as a partial agonist to active PKA signalling for modu-
lating Ca2+ channels, promoting insulin secretion. However, a Ca2+
and PKA signalling-independent mechanism induced by Phylloseptin-
PBu was likely to play a role in this action.
3.7 | Other mechanism examination for the
induction of insulin release by Phylloseptin-PBu
In order to assess whether other signalling is existed in regulating
Phylloseptin-PBu’s insulinotropic activity, we treated the cells using
diazoxide or verapamil together with H89, and measured the insulin
release. As the Figure 7 shown, compared with singular H89 treat-
ment, Phylloseptin-PBu still has moderately, but significantly higher
insulin release activity even co-treated with H89 and/or with diazox-
ide/verapamil, but this effect was completely abolished in the Ca2+-
free medium settings, which proposed a KATP- and PKA-independent
Ca2+ influx mechanism.
4 | DISCUSSION
In the postprandial state, elevated blood glucose is sensed by pan-
creatic beta-cells which in response secrete insulin to maintain glu-
cose homoeostasis. This process occurs under both physiological and
pathological conditions, and thus, increasing insulin release has
promising therapeutic potential.5
The mechanism correlated with acute insulin secretion in islets
has been well-studied, which is commonly summarized as two dis-
tinct pathways, one is related to the KATP channel closure, and
F IGURE 6 Acute effects (20 min stimulation) of 107 mol/L
Phylloseptin-PBu on the insulin release. BRIN-BD11 cells were
incubated with 1.1 mmol/L glucose, 5.6 mmol/L glucose,
16.7 mmol/L glucose, 10 mmol/L alanine, 300 lmol/L diazoxide,
60 lmol/L verapamil, 1 lmol/L exendin-(9-39) and 107 mol/L
Phylloseptin-PBu in the Ca2+ present or absent KRB buffer. Data
were analysed with unpaired Student’s t test using GraphPad Prism
5 software. Values are the mean  SEM for three independent
experiments. *P < .05 between indicated groups
F IGURE 7 Acute effects (20 min stimulation) of 107 mol/L
Phylloseptin-PBu on the insulin release. BRIN-BD11 cells were
incubated with 1.1 mmol/L glucose, 5.6 mmol/L glucose,
16.7 mmol/L glucose, 10 mmol/L alanine, 10 lmol/L H89,
300 lmol/L diazoxide, 60 lmol/L verapamil and 107 mol/L
Phylloseptin-PBu in the Ca2+ present or absent KRB buffer. Data
were analysed with unpaired Student’s t test using GraphPad Prism
5 software. Values are the mean  SEM for three independent
experiments. ** or ##P < .01 between indicated groups
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membrane depolarization-triggered intracellular calcium rise via Ca2+
channels on both cell membrane and endoplasmic reticulum, the
other one is through Ca2+-induced insulin secretory vesicle exocyto-
sis.31 In this study, we investigated the KATP-channel, calcium
channel, PKA signalling and GLP-1 receptor in regulating Phyl-
loseptin-PBu-induced insulinotropic effect in BRIN-BD11 cells, we
confirmed that this novel peptide stimulates acute insulin release at
physiological concentration of 5.6 mmol/L glucose by deactivating
KATP channels, leads to the opening of calcium channels and calcium
influx, which subsequently drives the fusion of secretory vesicles to
the plasma membrane for exocytosis of insulin. We also confirmed
that Phylloseptin-PBu partially stimulates GLP-1 receptor, resulting
in PKA activation for the increased insulin secretion. Notwithstand-
ing, it must be noticed that, in Figure 5, Ca2+-free medium remark-
ably decreased insulin output even under the condition of blocking
calcium channel using verapamil, suggested a novel cytosol Ca2+
import mechanism, which is further supported by the independent
results of Figure 7, and we suppose that ionotropic receptors (also
known as ligand-gated ion channels) might play the crucial role in it,
which warrants further investigations. Moreover, based on Figure 5
and part Figure 6 results, the novel peptide still enhanced insulin
release significantly compared with no Phylloseptin-PBu treatment
groups, which implied an intracellular Ca2+ store (endoplasmic reticu-
lum)-referred mechanism induced by Phylloseptin-PBu. In addition,
another interesting issue is that, in Figure 5A, we observed the addi-
tive augment insulin release effect of Phylloseptin-PBu with IBMX,
we presume that IBMX, as a phosphodiesterase inhibitor to raise
intracellular cAMP,36 has distinct PKA activation mechanism with
Phylloseptin-PBu, which involves activating of GLP-1 receptor, and
therefore, the hyperactive PKA by both Phylloseptin-PBu and IBMX
contributed to the dramatically increased insulin secretion.
In consideration of the secondary structure of Phylloseptin-PBu,
which could also be crucial for its biological relevance, we conducted
the CD analysis, the results showed that in 50% TFE aqueous solu-
tion, this novel peptide formed a well-defined a-helical structure,
while in polar solvent, much less of (7%) a-helicity was presented.
This result was similar to glucose-dependent insulinotropic polypep-
tide (GIP), GLP-1, extendin-4 and glucagon,37-40 likewise, we assume
that the full length of a-helical conformation might be important for
Phylloseptin-PBu to exert the insulin induction activity. Nonetheless,
further NMR or other structure-activity relationship studies are
needed for determination.
In addition, we also measured the insulinotropic activity of Phyl-
loseptin-PBu in 16.7 mmol/L glucose conditions to test whether it
could further enhance insulin release, the results showed that no
higher insulin release was observed (Figure S3). We speculate that
the high glucose level might induce the cells to be stressful, and in
such condition, the capacity of insulin release from cells could be
limited by the high baseline insulin release.
Overall, in this project, we isolated and identified a novel peptide
from Phyllomedusa burmeisteri, the insulinotropic effect of this novel
peptide Phylloseptin-PBu has been substantially studied, we con-
firmed the energy-mediated KATP and Ca
2+ channels, and the GLP-1
receptor initiated PKA activation involvements in this effect, which
has never been published from amphibian sources, our study contin-
uously provide novel candidate and fundamental understanding for
the treatment of T2DM in future.
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